OFT accuses GSK of market abuse over pay-for-delay deals


The UK Office of Fair Trading (OFT) has accused pharmaceutical firm GlaxoSmithKline (GSK) of abusing its market dominance and infringing UK competition law by paying rivals to delay releasing generic versions of its anti-depressant Seroxat.

GSK, market abuse, generic, Seroxat, OFT, competition, Alpharma, Norton Healthcare